66.04
0.05%
0.03
Dopo l'orario di chiusura:
66.04
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
0.41%
648.83
|
646.21 | 581.33 | 595.27 | 596.41 |
Cost Of Revenue |
7.60%
125.18
|
135.48 | 124.75 | 128.08 | 126.55 |
Gross Profit |
2.53%
523.65
|
510.73 | 456.58 | 467.19 | 469.87 |
Operating Expenses
|
12.35%
435.19
|
496.51 | 430.92 | 408.32 | 410.52 |
Interest Income/Expense |
41.83%
3.547
|
6.098 | 3.779 | 3.755 | 3.703 |
Benefits Costs and Expenses |
13.33%
543.29
|
626.88 | 539.66 | 524.47 | 539.66 |
Costs And Expenses |
11.33%
560.37
|
631.99 | 555.67 | 536.40 | 537.07 |
Operating Income/Loss |
522.14%
88.46
|
14.22 | 25.66 | 58.87 | 59.35 |
Income/Loss From Continuing Operations Before Tax |
446.11%
105.55
|
19.33 | 41.67 | 70.81 | 56.76 |
Income Tax Expense/Benefit, Deferred |
101.15%
0.285
|
-24.84 | -15.03 | 1.252 | -6.36 |
Income Tax Expense/Benefit |
1,711%
16.89
|
-1.048 | 1.291 | 14.77 | 5.905 |
Income/Loss From Continuing Operations After Tax |
335.15%
88.66
|
20.38 | 40.38 | 56.04 | 50.85 |
Net Income/Loss
|
335.15%
88.66
|
20.38 | 40.38 | 56.04 | 50.85 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
86,935%
188.87
|
0.217 | 188.22 | 187.95 | 186.67 |
Diluted Average Shares |
5,881%
199.26
|
-3.447 | 191.17 | 195.00 | 194.36 |
Basic Earnings Per Share |
327.27%
0.47
|
0.11 | 0.21 | 0.30 | 0.27 |
Diluted Earnings Per Share |
360.00%
0.46
|
0.10 | 0.21 | 0.29 | 0.27 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):